Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 24, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 24, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/24/17 - ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line
By a News Reporter-Staff News Editor at Biotech Week ABL, Inc., a leading contract research, development and biomanufacturing organization to the biopharmaceutical industry worldwide, is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a ne
5/24/17 - Agilis Biotherapeutics Announces Presentation of Data from Phase I/II Trial for Treatment of AADC Deficiency
The gene therapy treatment candidate, AGIL-AADC, is an adeno-associated virus vector containing the human gene for the AADC enzyme. Dr. Hwu stated, "We are pleased to present this important work highlighting the encouraging safety and efficacy observed to date in which AADC deficiency patients treated with the AGIL-AADC gene therapy have exhibited.
5/24/17 - Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors
By a News Reporter-Staff News Editor at Biotech Week Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., announced the appointment of Edward Fitzgerald to the company's board of directors. Mr. Fitzgerald, former executive vice president and chief financial officer of ARIAD Pharmaceuticals, joins Akcea's board of director
5/24/17 - Albireo Announces Proposed Public Offering of Common Stock [Ethiopian News Agency]
-Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering of its common stock. The offering will be made only by means of a written prospectus and related prospectus supplement forming part of a shelf registration statem
5/24/17 - ALUNBRIGTM brigatinib Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.
By a News Reporter-Staff News Editor at Biotech Week Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIGTM.
5/24/17 - Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency [Sudan Tribune]
-Ammonett Pharma LLC, a privately-held biotechnology company developing a novel, daily, orally-administered mini-pill Growth Hormone secretagogue, today announced that the European Medicines Agencys Committee for Orphan Medicinal Products issued a positive opinion recommending the Companys MK-0677 for designation as an orphan medicinal product...
5/24/17 - Array BioPharma, Boulder, Colo., VentiRx Pharmaceuticals, Seattle, Assigned Patent for Substituted Benzoazepines as Toll-Like Receptor Modulators
Array Biopharma, Boulder, Colorado, and Ventirx Pharmaceuticals, Seattle, have been assigned a patent developed by seven co-inventors for "substituted benzoazepines as toll-like receptor modulators." The co-inventors are James Jeffry Howbert, Redmond, Washington, Gregory Dietsch, Snohomish, Washington, Robert Hershberg, Seattle, Laurence E. Burgess
5/24/17 - Biogen buys Remedy Pharmaceuticals` stroke drug Cirara [Syrian Arab News Agency]
Biogen last week completed an asset purchase of Remedy Pharmaceuticals phase 3 candidate, Cirara. The US Food and Drug Administration recently granted Cirara Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. Each year approximately 1.7 million ischemic strokes occur across the US, Europe and Japan, and...
5/24/17 - Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics [Algeria Press Service]
Bioverativ Inc., a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, today announced that it has entered into a definitive agreement to acquire South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease
5/24/17 - CANbridge Raises $25M Series B Financing [T-break Tech (Middle East)]
CANbridge Life Sciences, a Beijing, China- based clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, raised $25 m in Series B funding. Led by James Xue, PhD, Chairman and CEO, CANbridge is a clinical-stage bio-pharmaceutical company accelerating development and commercialization of special
5/24/17 - Caprion Biosciences Inc. will present at the 5th Annual Biopharmaceutical Emerging Best Practices Association BEBPA Conference highlighting the...
Caprion Biosciences Inc. will present at the 5th Annual Biopharmaceutical Emerging Best Practices Association BEBPA Conference highlighting the latest developments in Host Cell Protein HCP analysis. By a News Reporter-Staff News Editor at Biotech Week Caprion Biosciences Inc. a worldwide leading specialty CRO laboratory announced that Dr.
5/24/17 - Curetis Provides Business and Financial Update for the First Quarter 2017
Recent Operational and Business Highlights Unyvero U.S. FDA Trials* In January 2017, Curetis filed a 510 application with the U.S. Food and Drug Administration to obtain clearance for its Unyvero Platform and LRT Application Cartridge. The submission is based on clinical data from the Company's U.S. FDA trial comparing the performance of the Unyver
5/24/17 - Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
Curetis Provides Update on Unyvero LRT FDA 510 Submission- Curetis reiterates that it expects FDA to provide decision on clearance of Unyvero LRT in the second half of 2017 Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 24, 2017- Curetis N.V., a developer of next-level molecular diagnostic solutions, today provided an update regarding
5/24/17 - Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial [Sudan Tribune]
-Cytori Therapeutics, Inc., today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subjects 48 week visit was conducted earlier this week. In the United States, the scleroderma affected population appears to be approximately 1
5/24/17 - Data on Transdermal Delivery Reported by Researchers at University of California (Deformable Nanovesicles Synthesized through an Adaptable...
Data on Transdermal Delivery Reported by Researchers at University of California. Financial supporters for this research include Mary S. Easton Center for Alzheimer s Disease Research, National Institutes of Health. The news reporters obtained a quote from the research from the University of California, "To determine the ability of DNV-encapsula
5/24/17 - Data on Vaccines Detailed by Researchers at GlaxoSmithKline plc (Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of...
Data on Vaccines Detailed by Researchers at GlaxoSmithKline plc. By a News Reporter-Staff News Editor at Vaccine Weekly Investigators discuss new findings in Immunization- Vaccines. The news reporters obtained a quote from the research from GlaxoSmithKline plc, "360 adults >= 65 years of age in stable health received either 1 of 4 adjuvanted A/ma
5/24/17 - Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset From ImmunoGen
Transaction a dds i nnovative c linical- s tage p rogram to e xpanding Debiopharm p ortfolio and broadens its clinical development expertise. Debiopharm International SA, part of Debiopharm Group?, a Switzerland- based biopharmaceutical company, and ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of
5/24/17 - FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. "This is an important first for the cancer community," said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncolog
5/24/17 - FDA approves Merck's bladder cancer drug
The FDA has approved two new indications for Merck's Keytruda (pembrolizumab), the company's anti-PD-1 therapy, for bladder cancer...
5/24/17 - FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis
-Actemra/RoActemra is the first FDA- approved treatment for adults with giant cell arteritis. -FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA. "Today's FDA decision means people living with giant cell arteritis will, for the first time, have an FDA- approved treatment option for this debili
5/24/17 - Findings from Pfizer Reveals New Findings on Follicular Lymphoma (Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the...
By a News Reporter-Staff News Editor at Biotech Week New research on Oncology- Follicular Lymphoma is the subject of a report. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma. The news correspondents obtained a quote fro
5/24/17 - Findings from Rice Research Institute Provides New Data about Plant Biotechnology (Generation of targeted mutant rice using a CRISPR-Cpf1 system)
According to news reporting out of Hefei, People's Republic of China, by NewsRx editors, research stated, "CRISPR-Cpf1 is a newly identified CRISPR-Cas system, and Cpf1 was recently engineered as a molecular tool for targeted genome editing in mammalian cells. For more information on this research see: Generation of targeted mutant rice using a CRI
5/24/17 - Generational Equity Announces Sale of Safis Solutions to PharmaLex Group
By a News Reporter-Staff News Editor at Biotech Week Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Safis Solutions LLC, to the PharmaLex Group. Safis Solutions, headquartered in Indianapolis, Indiana, assists pharmaceutical, medical device and biotech
5/24/17 - Global Gummy Vitamin Industry Segment by Applications, Product Type and Forecast to 2022
It is the chewiness and flavorings that make them attractive to children and adults alike, as chewing gummies vitamins is more convenient than swallowing pills for any one. Scope of the Report: This report focuses on the Gummy Vitamin in Global Market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.
5/24/17 - GUEST COLUMN
Driving near Monterey, California, recently, I stopped at a roadside stand to buy some freshly picked strawberries. When I told him I work for Medicare, he said he was having difficulty paying for his prescription drugs. If you have Medicare and you're having trouble paying for prescription drugs, signing up for Medicare's Part D prescription drug
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement